@article{Standing_J-2024_169607,
title = {Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients},
author = {Standing, J. and Buggiotti, L. and Guerra-Assuncao, J. and Woodall, M. and Ellis, S. and Agyeman, A. and Miller, C. and Okechukwu, M. and Kirkpatrick, E. and Jacobs, A. and Williams, C. and Roy, S. and Martin-Bernal, L. and Williams, R. and Smith, C. and Sanderson, T. and Ashford, F. and Emmanuel, B. and Afzal, Z. and Sheilds, A. and Richter, A. and Dorward, J. and Gbinigie, O. and Lown, M. and Francis, N. and Jani, B. and Richards, D. and Rahman, N. and Yu, L. and Thomas, N. and Hart, N. and Evans, P. and Andersson, M. and Hayward, G. and Hood, K. and Nguyen-Van-Tam, J. and Little, P. and Hobbs, F. and Khoo, S. and Butler, C. and Lowe, D. and Breuer, J. and van Hecke, O.},
month = {feb},
year = {2024},
abstract = {Viral clearance, antibody response and the mutagenic effect of molnupiravir has not 77 been elucidated in at-risk populations. Non-hospitalised participants within 5 days of 78 SARS-CoV-2 symptoms randomised to receive molnupiravir (n=253) or Usual Care 79 (n=324) were recruited to study viral and antibody dynamics and the effect of molnupiravir on viral whole genome sequence from 1437 viral genomes. Molnupiravir accelerates viral load decline, but virus is detectable by Day 5 in most cases. At Day 14 (9 days post-treatment), molnupiravir is associated with significantly higher viral persistence and significantly lower anti-SARS-CoV-2 spike antibody titres compared to Usual Care. Serial sequencing reveals increased mutagenesis with molnupiravir treatment. Persistence of detectable viral RNA at Day 14 in the molnupiravir group is associated with higher transition mutations following treatment cessation. Viral viability at Day 14 is similar in both groups with post-molnupiravir treated samples cultured up to 9 days post cessation of treatment. The current 5-day molnupiravir course is too short. Longer courses should be tested to reduce the risk of potentially transmissible molnupiravir-mutated variants being generated.},
volume = {15},
journal = {Nature Communications},
publisher = {Springer Nature},
url = {https://doi.org/10.1038/s41467-024-45641-0},
}
